Zhitong Finance App News, China Pharmaceutical (600056.SH) issued an announcement. Recently, Tianfang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Approval of the Marketing Application for Chemical Ingredients” with the approval and issuance of ezetimab by the State Drug Administration. This drug is mainly used for primary hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH), homozygous sitosterolemia (or phytosterolemia). The approval of this API will further expand the company's product field and improve the layout of API products in the cardiovascular field.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.